Modified Immune Effector Cell Committee

The Modified Immune Effector Cell Committee designs annual ASGCT programming related to the development and application of modified immune effector cells. This includes the optimization of safe and effective CAR T cells, NK cells, and TILs as well as the continued discovery and innovation of other modified immune effector cells and the translation of these technologies into genetic medicines
Full NamePositionOrganizationTerm StartTerm End
Isabelle Riviere, PhDChairTakeda, Cambridge, MA9/19/20255/31/20271446
He HuangMember 10/13/20255/31/202864851
Andreas MackensenMemberFriedrich-Alexander University Erlangen-Nuremberg10/24/20255/31/202877491
Justin Eyquem, PhDMemberUCSF9/19/20255/31/202825446
Catherine M. Bollard, MDMemberThe George Washington University9/19/20255/31/20288841
Lili Yang, PhDMemberUniversity of California Los Angeles9/25/20255/31/202823468
Maksim Mamonkin, PhDMemberColumbia University9/21/20255/31/202823681
Maria Themeli, MD PhDMemberAmsterdam UMC9/25/20255/31/202845600
Shon Green, PhDMemberZelig Therapeutics9/19/20255/31/202869395
Leo David Wang, MD, Ph.D.MemberCity of Hope National Medical Center9/19/20255/31/202860781
Marlene Carrasco AlfonsoMember 6/1/20265/31/202952443
Danielle GaleStaff LiaisonASGCT9/19/20255/31/203535359